41.67 0.00 (0.00%)
After hours: 4:26PM EDT
|Bid||40.00 x 1100|
|Ask||44.00 x 800|
|Day's Range||40.93 - 41.83|
|52 Week Range||27.23 - 44.87|
|PE Ratio (TTM)||21.52|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Myriad (MYGN) likely to deliver solid Q4 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Myriad (MYGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Shares of molecular diagnostic company Myriad Genetics, Inc. (NASDAQ: MYGN ) have 45-percent upside potential, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded shares of Myriad Genetics ...
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Myriad Genetics Inc (NASDAQ:MYGN) with a market-capitalization of US$2.72b, rarely draw their attention. However, generally ignored mid-capsRead More...
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 19. Index (PMI) data, output in the Healthcare sector is rising.
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
On June 18, Myriad Genetics (MYGN) announced that the FDA accepted its supplementary premarket approval (or sPMA) application for BRACAnalysis CDx, a companion diagnostic with Pfizer’s (PFE) talazoparib, a PARP (poly ADP ribose polymerase) inhibitor. Pfizer has already filed a new drug application (or NDA) for the approval of talazoparib. The FDA has granted Pfizer’s NDA for talazoparib “priority review” status and provided a Prescription Drug User Fee Act action date of December 2018.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Counsyl Inc. is the latest in a string of exits for startups offering noninvasive prenatal genetic tests. Inc. said it would pay $375 million in cash and stock for Counsyl, a venture-backed provider of carrier screening and prenatal genetic tests. Ariosa Diagnostics, another venture-backed company in this market, was acquired by Roche in 2014.
Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.
This increased rate in commercial insurer coverage for Myriad Genetics' (MYGN) Prolaris comes close on the heels of the NCCN guidelines.
Stocks with market capitalization between $2B and $10B, such as Myriad Genetics Inc (NASDAQ:MYGN) with a size of US$2.33B, do not attract as much attention from the investing community asRead More...
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
Molecular diagnostics and personalized medicine company Myriad Genetics, Inc. (NASDAQ: MYGN ) announced its fiscal third-quarter financial results Tuesday. What Happened Myriad Genetics reported better-than-expected ...
The Salt Lake City-based company said it had net income of 16 cents per share. Earnings, adjusted for one-time gains and costs, were 31 cents per share. The results topped Wall Street expectations. The ...